A randomized Phase 2a substudy evaluated participants with elevated liver fat. Its main measure was relative change in liver fat at 24 weeks, assessed within a selected group from the obesity study.
Liver fat measured in a defined subgroup
In the 12 mg group, the paper reported an average relative reduction in liver fat of 82.4%, compared with a 0.3% increase in the placebo group. This is a liver-fat measure, separate from body-weight change.
How to interpret the evidence
The study population and imaging endpoint matter. These results do not establish outcomes such as reduced cirrhosis or long-term liver-related events.
This research summary focuses on a defined endpoint or safety observation. Its relevance depends on the study’s population and follow-up.